GPs support $590m investment in take-private target China Biologic
China Biologic Products, a US-listed biopharmaceuticals player that was subject to two take-private offers, said it was set to raise $590 million by issuing new shares to investors including Centurium Capital, CITIC Capital, and Hillhouse Capital.
The three private equity firms have agreed to purchase 5.05 million shares at $100.90 apiece, the same as the August 23 closing price but a 22.5% premium to the price prior to the submission of the first...
More on Greater China
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.